Mabpharm opens $195m HK IPO, Hansoh kicks off PDIE

capsule px230
By Jonathan Breen
23 May 2019

Biopharmaceuticals company Mabpharm launched bookbuilding for its up to HK$1.53bn ($195m) flotation, while Hansoh Pharmaceutical Group set pre-marketing in motion for its Hong Kong listing.

Mabpharm is pre-revenue, taking advantage of the HKEX rule added in April last year that allows such biotechnology companies to list. It recorded losses of Rmb149.8m ($21.7m) in 2018 and Rmb47.7m the year before.

The company is offering 783.6m shares, which sole sponsor, global co-ordinator and bookrunner CICC is ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access:

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: or find out more online here.